These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 22691759)

  • 41. High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis.
    Schmierer K; Parkes HG; So PW; An SF; Brandner S; Ordidge RJ; Yousry TA; Miller DH
    Brain; 2010 Mar; 133(Pt 3):858-67. PubMed ID: 20123726
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Spinal cord MRI in multiple sclerosis--diagnostic, prognostic and clinical value.
    Kearney H; Miller DH; Ciccarelli O
    Nat Rev Neurol; 2015 Jun; 11(6):327-38. PubMed ID: 26009002
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Magnetization transfer imaging to monitor the evolution of individual multiple sclerosis lesions.
    Filippi M
    Neurology; 1999; 53(5 Suppl 3):S18-22. PubMed ID: 10496206
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Magnetic resonance and multiple sclerosis II. New diagnostic techniques].
    Mathiesen HK; Langkilde AR; Larsson HB
    Ugeskr Laeger; 2002 Feb; 164(8):1031-6. PubMed ID: 11894703
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Magnetic resonance imaging in multiple sclerosis].
    Tourbah A; Berry I
    Pathol Biol (Paris); 2000 Mar; 48(2):151-61. PubMed ID: 10815291
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Cerebral and spinal MRI examination in patients with clinically isolated syndrome and definite multiple sclerosis].
    Sailer M; Fazekas F; Gass A; Kappos L; Radue EW; Rieckmann P; Toyka K; Wiendl H; Bendszus M
    Rofo; 2008 Nov; 180(11):994-1001. PubMed ID: 18937154
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years.
    Rovaris M; Judica E; Gallo A; Benedetti B; Sormani MP; Caputo D; Ghezzi A; Montanari E; Bertolotto A; Mancardi G; Bergamaschi R; Martinelli V; Comi G; Filippi M
    Brain; 2006 Oct; 129(Pt 10):2628-34. PubMed ID: 16921179
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MRI and cognition in multiple sclerosis.
    Filippi M; Rocca MA
    Neurol Sci; 2010 Nov; 31(Suppl 2):S231-4. PubMed ID: 20635114
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of brain lesions in a mouse model of progressive multiple sclerosis.
    Levy H; Assaf Y; Frenkel D
    Exp Neurol; 2010 Nov; 226(1):148-58. PubMed ID: 20736006
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Spinal cord grey matter lesions in multiple sclerosis detected by post-mortem high field MR imaging.
    Gilmore CP; Geurts JJ; Evangelou N; Bot JC; van Schijndel RA; Pouwels PJ; Barkhof F; Bö L
    Mult Scler; 2009 Feb; 15(2):180-8. PubMed ID: 18845658
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Relevance of Magnet Resonance Tomography in the Diagnosis and Assessment of Course of Disease in Patients with Multiple Sclerosis].
    Lukas C; Sailer M
    Fortschr Neurol Psychiatr; 2015 Sep; 83(9):522-32; quiz 533-4. PubMed ID: 26421860
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association between pathological and MRI findings in multiple sclerosis.
    Filippi M; Rocca MA; Barkhof F; Brück W; Chen JT; Comi G; DeLuca G; De Stefano N; Erickson BJ; Evangelou N; Fazekas F; Geurts JJ; Lucchinetti C; Miller DH; Pelletier D; Popescu BF; Lassmann H;
    Lancet Neurol; 2012 Apr; 11(4):349-60. PubMed ID: 22441196
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Challenges in multiple sclerosis; how to define occurence of progression.
    Brinar VV; Barun B
    Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S30-4. PubMed ID: 24321151
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Progressive multiple sclerosis and gray matter pathology: an MRI perspective.
    Inglese M; Oesingmann N; Casaccia P; Fleysher L
    Mt Sinai J Med; 2011; 78(2):258-67. PubMed ID: 21425269
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of magnetic resonance imaging and immunotherapy in treating multiple sclerosis.
    Zhang J; Hutton G
    Annu Rev Med; 2005; 56():273-302. PubMed ID: 15660513
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Present and future of fMRI in multiple sclerosis.
    Filippi M; Rocca MA
    Expert Rev Neurother; 2013 Dec; 13(12 Suppl):27-31. PubMed ID: 24289839
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multiple sclerosis.
    Filippi M; Preziosa P; Rocca MA
    Handb Clin Neurol; 2016; 135():399-423. PubMed ID: 27432676
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Microstructural MR Imaging Techniques in Multiple Sclerosis.
    Filippi M; Preziosa P; Rocca MA
    Neuroimaging Clin N Am; 2017 May; 27(2):313-333. PubMed ID: 28391789
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Advances in ultra-high field MRI for the clinical management of patients with brain tumors.
    Lupo JM; Li Y; Hess CP; Nelson SJ
    Curr Opin Neurol; 2011 Dec; 24(6):605-15. PubMed ID: 22045220
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Very early MS--insights from MRI.
    Simon J
    Mult Scler; 2012 Oct; 18(10):1372-6. PubMed ID: 22760097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.